Development of Live Vaccine Candidates for Canine Influenza H3N2 Using Naturally Truncated NS1 Gene

Table 2

Groups of mice experiment for efficacy evaluation.

Group	n	Vaccines (HAU, volume)	Route	Challenge (titer, volume)
Caniflu IM (2^8)	28	CaniFlu-max (2^7HAU, 50 μl)	Intramuscular	CIV (10^6.5 EID50/mouse, 30 μl)
Caniflu IM (2^6)	28	CaniFlu-max (2^6HAU, 25 μl)	Intramuscular	CIV (10^6.5 EID50/mouse, 30 μl)
CIV^SA1 IN (2^6)	28	CIV^SA1 (2^6HAU, 25 μl)	Intranasal	CIV (10^6.5 EID50/mouse, 30 μl)
CIV^SA1 IM (2^6)	28	CIV^SA1 (2^6HAU, 25 μl)	Intramuscular	CIV (10^6.5 EID50/mouse, 30 μl)
P.C.	23	PBS (25 μl)	Intranasal	CIV (10^6.5 EID50/mouse, 30 μl)
N.C.	15	PBS (25 μl)	Intranasal	PBS (30 μl)